Tvardi Therapeutics (TVRD) Other Non Operating Income (2015 - 2025)
Tvardi Therapeutics (TVRD) posted Other Non Operating Income of $12.7 million for Q2 2025, up 3548.13% sequentially from $347000.0 in Q1 2025, and up 1737.3% YoY from $689000.0 in Q2 2024.
Tvardi Therapeutics (TVRD) Other Non Operating Income (2015 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Other Non Operating Income for 11 years, with the latest figure at $12.7 million in Q2 2025.
- Quarterly Other Non Operating Income rose 1737.3% year-over-year to $12.7 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $13.0 million (up 738.49% YoY) and the FY2025 annual result came in at $7.2 million, up 451.45% from the prior year.
- Other Non Operating Income climbed to $12.7 million in Q2 2025 per TVRD's latest filing, from $347000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $12.7 million in Q2 2025 and troughed at -$4.4 million in Q4 2024.
- A 5-year average of $958777.8 and a median of $677000.0 in 2022 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income plunged 608.47% in 2024, then soared 1737.3% in 2025.
- Over 5 years, Other Non Operating Income stood at $140000.0 in 2021, then jumped by 591.43% to $968000.0 in 2022, then retreated by 9.71% to $874000.0 in 2023, then slumped by 608.47% to -$4.4 million in 2024, then soared by 384.86% to $12.7 million in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $12.7 million, $347000.0, and -$4.4 million for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 12.66 Mn |
| Mar 31, 2025 | 347,000.00 |
| Dec 31, 2024 | -4.44 Mn |
| Sep 30, 2024 | 766,000.00 |
| Jun 30, 2024 | 689,000.00 |
| Mar 31, 2024 | 952,000.00 |
| Dec 31, 2023 | 874,000.00 |
| Sep 30, 2023 | 866,000.00 |
| Jun 30, 2023 | 861,000.00 |
| Mar 31, 2023 | 985,000.00 |
| Dec 31, 2022 | 968,000.00 |
| Sep 30, 2022 | 665,000.00 |
| Jun 30, 2022 | 266,000.00 |
| Mar 31, 2022 | 162,000.00 |
| Dec 31, 2021 | 140,000.00 |
| Sep 30, 2021 | 111,000.00 |
| Jun 30, 2021 | 131,000.00 |
| Mar 31, 2021 | 260,000.00 |
| Dec 31, 2020 | 364,000.00 |
| Sep 30, 2020 | 379,000.00 |